{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T18:22:12Z","timestamp":1774117332377,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T00:00:00Z","timestamp":1391817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.rmed.2014.01.002","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T16:30:18Z","timestamp":1389803418000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale"],"prefix":"10.1016","volume":"108","author":[{"given":"Helgo","family":"Magnussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Kirsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Decramer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.A.","family":"Calverley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lesley","family":"Towse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Finnigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Tetzlaff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Disse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2014.01.002_bib1","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2014.01.002_bib2","series-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2013"},{"key":"10.1016\/j.rmed.2014.01.002_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1183\/09031936.00048912","article-title":"The role of bronchodilator treatment in the prevention of exacerbations of COPD","volume":"40","author":"Wedzicha","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/09031936.00200212","article-title":"Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study","author":"Bateman","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1183\/09031936.05.00140404","article-title":"Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD","volume":"26","author":"van Noord","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1164\/rccm.201207-1299OC","article-title":"Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population","volume":"186","author":"Lange","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000315416","article-title":"Inhaled corticosteroids in COPD: a controversy","volume":"80","author":"Barnes","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2014.01.002_bib10","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/bmj.320.7245.1297","article-title":"Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial","volume":"320","author":"Burge","year":"2000","journal-title":"Br Med J"},{"key":"10.1016\/j.rmed.2014.01.002_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00193908","article-title":"Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results","volume":"34","author":"Crim","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib12","unstructured":"Ferguson GT. Effect of salmeterol\/fluticasone propionate (SFC) on bone mineral density (BMD) and eye disorders over three years in the TORCH Trial. In: Abstract A763 presented at the 103rd Annual International Conference of the American Thoracic Society, San Francisco, California, USA, 18\u201323 May 2007."},{"key":"10.1016\/j.rmed.2014.01.002_bib13","first-page":"587","article-title":"Effects of inhaled corticosteroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta-analysis","volume":"7","author":"Jen","year":"2012","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.rmed.2014.01.002_bib14","first-page":"CD002991","article-title":"Inhaled corticosteroids for stable chronic obstructive pulmonary disease","volume":"7","author":"Yang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmed.2014.01.002_bib15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2174\/1389450111314020006","article-title":"Inhaled corticosteroids in COPD: pros and cons","volume":"14","author":"Zervas","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.rmed.2014.01.002_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1378\/chest.08-3016","article-title":"Prevalence and progression of osteoporosis in patients with COPD. Results from the towards a revolution in COPD health study","volume":"136","author":"Ferguson","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2014.01.002_bib18","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0140-6736(09)61250-2","article-title":"Budesonide and the risk of pneumonia: a meta-analysis of individual patient data","volume":"374","author":"Sin","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.rmed.2014.01.002_bib19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S2213-2600(13)70040-7","article-title":"Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials","volume":"1","author":"Dransfield","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib20","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","article-title":"Susceptibility to exacerbation in chronic obstructive pulmonary disease","volume":"363","author":"Hurst","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib21","doi-asserted-by":"crossref","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","article-title":"Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype","volume":"7","author":"Agusti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2014.01.002_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1164\/rccm.201209-1665OC","article-title":"Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease","volume":"187","author":"Vanfleteren","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib23","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/thoraxjnl-2012-201871","article-title":"Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease","volume":"68","author":"Duvoix","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2014.01.002_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1046\/j.1365-2222.1998.00243.x","article-title":"Changes in sputum composition during sputum induction in healthy and asthmatic subjects","volume":"28","author":"Holz","year":"1998","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.rmed.2014.01.002_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/thoraxjnl-2012-202959","article-title":"Inhaled corticosteroids in COPD: quantifying risks and benefits","volume":"68","author":"Cates","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2014.01.002_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1465-9921-12-107","article-title":"Withdrawal of inhaled corticosteroids in individuals with COPD \u2013 a systematic review and comment on trial methodology","volume":"12","author":"Nadeem","year":"2011","journal-title":"Respir Res"},{"key":"10.1016\/j.rmed.2014.01.002_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pcrj.2003.11.005","article-title":"Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice","volume":"13","author":"Schermer","year":"2004","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib28","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/thx.2004.034280","article-title":"Withdrawal of fluticasone propionate from combined salmeterol\/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial","volume":"60","author":"Wouters","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.rmed.2014.01.002_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1465-9921-8-93","article-title":"Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial","volume":"8","author":"Choudhury","year":"2007","journal-title":"Respir Res"},{"key":"10.1016\/j.rmed.2014.01.002_bib30","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1164\/rccm.200206-512OC","article-title":"Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study","volume":"166","author":"van der Valk","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1183\/09031936.00098307","article-title":"Methodological issues in therapeutic trials of COPD","volume":"31","author":"Suissa","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmed.2014.01.002_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0954-6111(99)90001-X","article-title":"An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease","volume":"93","author":"Jarad","year":"1999","journal-title":"Respir Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib33","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/ajrccm.163.2.9912091","article-title":"Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids","volume":"163","author":"Leuppi","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmed.2014.01.002_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1183\/09031936.00190908","article-title":"Inhaled corticosteroids in COPD: the case against","volume":"34","author":"Suissa","year":"2009","journal-title":"Eur Respir J"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611114000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611114000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:29:38Z","timestamp":1760614178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611114000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0954611114000225"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2014.01.002","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2014.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}